Maria Cantwell Questions HHS Nominee on NIH Funding Cuts and PBM Transparency

NIH Funding and Research Integrity

• ❓ Senator Cantwell directly questioned HHS nominee James O'Neill regarding support for proposed $18 billion cuts to NIH funding.
• 💡 O'Neill stated he had no involvement in budget development but emphasized the importance of pursuing gold standard research and ensuring funding for replicable studies.
• 🔬 When pressed if the proposed cuts seemed reasonable, O'Neill explained the proposal aimed to reduce duplication by combining institutes, though he had not reviewed the budget's specific details.
• 🏥 Cantwell highlighted the role of NIH investment and innovation in addressing rising healthcare costs associated with an aging population, citing Alzheimer's research as an example.

PBM Transparency and Drug Costs

• 📈 Cantwell raised concerns about Pharmacy Benefit Managers (PBMs), citing FTC findings of significant markups on drugs, with one example showing a 7,736% increase for a hypertension drug.
• 💰 She also noted PBMs profited $1.4 billion from spread pricing, pocketing savings instead of passing them to payers like Medicare.
• ✅ O'Neill expressed support for increasing transparency and accountability in the PBM market and the broader drug supply chain to drive down prices.
• 🤝 He stated a preference for increased competition in drugs and throughout the supply chain.

Drug Price Negotiation and State Innovation

• 🗣️ O'Neill acknowledged the CMS experiment in negotiating drug prices, stating HHS should use its authority to lower costs for taxpayers and patients.
• ⚖️ He affirmed support for enacting such laws vigorously to promote competition, provided they are the law.
• 💡 Regarding state-level initiatives like the Basic Health Plan, O'Neill expressed broad sympathy for the principle of states acting as laboratories of innovation to improve healthcare delivery and fund usage.